In rodents and primary cells, administration of D-JNK1-1, a cell-permeable JNK1 inhibiting peptide, resulted in decreased AT8 (pSer202/pSer205) immunoreactivity [165], further supporting the role of JNK in tauopathy pathogenesis. The gene discussed is MAPK8; the disease is tauopathy.